F

Fate Therapeutics

FATE

4.88000
USD
-0.46
(-8.61%)
Market Open
Volume
13,516
EPS
0
Div Yield
0
P/E
-2
Market Cap
364,409,229
Related Instruments
A
ALLO
-0.21500
(-7.29%)
2.73500 USD
B
BLUE
-0.06000
(-5.26%)
1.08000 USD
C
CLLS
-0.11000
(-4.89%)
2.14000 USD
C
CRSP
-2.450
(-4.28%)
54.840 USD
E
EDIT
-0.28500
(-5.26%)
5.13500 USD
S
SGMO
-0.09690
(-12.11%)
0.70340 USD
News

Title: Fate Therapeutics

Sector: Healthcare
Industry: Biotechnology
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.